• 1
    O'Byrne PM. Allergen-induced airway inflammation and its therapeutic intervention. Allergy Asthma Immunol Rev 2009;1:39.
  • 2
    Cockcroft DW, Hargreave FE, O'Byrne PM, Boulet LP. Understanding allergic asthma from allergen inhalation tests. Can Respir J 2007;14:414418.
  • 3
    O'Byrne PM, Dolovich J, Hargreave FE. Late asthmatic responses. Am Rev Respir Dis 1987;136:740751.
  • 4
    Gauvreau GM, Evans MY. Allergen inhalation challenge: a human model of asthma exacerbation. Contrib Microbiol 2007;14:2132.
  • 5
    Inman MD, Watson R, Cockroft DW, Wong BJ, Hargreave FE, O'Byrne P. Reproducibility of allergen-induced early and late asthmatic responses. J Allergy Clin Immunol 1995;95:11911195.
  • 6
    Gauvreau GM, Doctor J, Watson RM, Jordana M, O'Byrne PM. Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med 1996;154:12671271.
  • 7
    Kelly MM, O'Connor TM, Leigh R, Otis J, Gwozd C, Gauvreau GM et al. Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma. J Allergy Clin Immunol 2010;125:349356.
  • 8
    Lötvall J, Ekerljung L, Rönmark EP, Wennergren G, Lindén A, Rönmark E et al. West Sweden Asthma Study: prevalence trends over the last 18 years argues no recent increase in asthma. Respir Res 2009;10:94.
  • 9
    Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011;127:355360.
  • 10
    Busse WW, Bleecker ER, Bateman ED, Lötvall J, Forth R, Davis AM et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax 2012;67:3541.
  • 11
    Bleecker ER, Bateman ED, Busse W, Lötvall J, Woodcock A, Tomkins S et al. Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy. Ann Allergy Asthma Immunol 2012;109:353358.
  • 12
    Bateman ED, Bleecker ER, Busse W, Lötvall J, Woodcock A, Forth R et al. Fluticasone furoate (FF), a once-daily inhaled corticosteroid (ICS), demonstrates dose-response efficacy in patients symptomatic on non-steroidal asthma therapy. Respir Med 2012;106:642650.
  • 13
    Lötvall J, Bateman ED, Bleecker ER, Busse W, Woodcock A, Follows R et al. Dose-related efficacy of vilanterol trifenatate (VI), a long-acting beta2 agonist (LABA) with inherent 24-hour activity, in patients with persistent asthma. Eur Respir J 2012;40:570579.
  • 14
    Sterling R, Lim J, Frith L, Snowise NG, Jacques L, Haumann B. Efficacy and optimal dosing interval of the long-acting beta2 agonist, vilanterol, in persistent asthma: a randomised trial. Respir Med 2012;106:11101115.
  • 15
    Global initiative for asthma: Global strategy for asthma management and prevention. Updated 2011. Available at: Last Accessed 29 July 2012.
  • 16
    Inman MD, Watson RM, Rerecich T, Gauvreau GM, Lutsky BN, Stryszak P. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med 2001;164:569574.
  • 17
    Gauvreau GM, Lee JM, Watson RM, Irani AM, Schwartz LB, O'Byrne PM. Increased numbers of both airway basophils and mast cells in sputum after allergen inhalation challenge of atopic asthmatics. Am J Respir Crit Care Med 2000;161:14731478.
  • 18
    Lötvall J, Pamqvist M, Arvisson P. Comparing the effects of two inhaled glucocorticoids on allergen-induced bronchoconstriction and markers of systemic effects, a randomised cross-over double-blind study. Clin Transl Allergy 2011;1:12.
  • 19
    Malmhäll C, Bossios A, Pullerits T, Lötvall J. Effects of pollen and nasal glucocorticoid on FOXP3 + , GATA-3 + and T-bet+ cells in allergic rhinitis. Allergy 2007;62:10071013.
  • 20
    Salter M, Biggadike K, Matthews JL, West MR, Haase MV, Farrow SN et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007;293:660667.
  • 21
    Ito K, Rossios C, Adcock IM, Barnes PJ, Johnson M. Fluticasone furoate, a novel enhanced-affinity inhaled corticosteroid (ICS), with sustained glucocorticoid receptor nuclear translocation. Am J Respir Crit Care Med 2010;181:A5409.
  • 22
    To M, To Y, Rossios C, Barnes PJ, Adcock IM, Johnson M et al. Fluticasone furoate, a novel enhanced-affinity inhaled corticosteroid (ICS), has more potent anti-inflammatory effects than fluticasone propionate in peripheral blood mononuclear cells from asthma and COPD patients. Am J Respir Crit Care Med 2010;181:A4454.
  • 23
    Dahlén B, Lantz AS, Ihre E, Skedinger M, Henriksson E, Jörgensen L et al. Effect of formoterol with or without budesonide in repeated low-dose allergen challenge. Eur Respir J 2009;33:747753.
  • 24
    van der Woude HJ, Boorsma M, Bergqvist PBF, Winter TH, Aalbers R. Budesonide/formoterol in a single inhaler rapidly relieves methacholine induced moderate-to-severe bronchoconstriction. Pulm Pharm Ther 2004;17:8995.
  • 25
    Oliver A, Quinn D, Goldfrad C, van Hecke B, Ayer J, Boyce M. Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial. Clin Transl Allergy 2012;2:11.